AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
NCT ID NCT07678619
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and evaluation tools. Around 780 CDC staff across five Chinese provinces will use the toolkit alongside their usual methods, and their response times will be compared to those who follow routine practices only.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SMART-ID Toolkit (AI-driven decision-support software)
What this could lead to
If successful, this AI toolkit could help public health officials respond to outbreaks faster and more effectively, potentially saving lives during future epidemics.
What could go wrong
This is a relatively small, early-stage study in five Chinese provinces. The toolkit may not work as well in other regions or with different diseases, and real-world effectiveness remains unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jue Liu
Beijing, Beijing Municipality, 100191, China